Losartan Potassium
Product Images NDC 50090-3409

6 FDA label images from A-s Medication Solutions · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 50090-3409). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label Image (Lbl500903409)

Label Image (Lbl500903409)
Losartan Potassium 100 mg tablet label from A-S Medication Solutions. The label includes storage instructions to keep the product at 68 to 77 degrees Fahrenheit and protect it from light. This package contains 30 tablets. The NDC number 50090-3409 is visible along with other manufacturing and packaging information.*
FDA Label Image

Figure 1 (Losartan Fig1)

Figure 1 (Losartan Fig1)
A line graph comparing the percentage of patients with primary endpoint events over study months for Atenolol (dotted line) and Losartan Potassium (solid line). The x-axis shows study duration in months (0 to 66), and the y-axis shows percentage of patients (0 to 16%). The graph includes an annotation indicating an adjusted risk reduction of 13% with a p-value of 0.021 for Losartan Potassium compared to Atenolol.*
FDA Label Image

Figure 2 (Losartan Fig2)

Figure 2 (Losartan Fig2)
A line graph comparing percent of patients with fatal or non-fatal stroke over study months up to 66 months for Losartan Potassium versus Atenolol. The graph shows a continuous progression with a lower stroke rate in the Losartan Potassium group, indicating a 25% adjusted risk reduction with statistical significance (p=0.001).*
FDA Label Image

Figure 3 (Losartan Fig3)

Figure 3 (Losartan Fig3)
Figure 3 presents a forest plot comparing primary composite and stroke (fatal/non-fatal) event rates between Losartan Potassium and Atenolol across demographic subgroups. It includes hazard ratios with 95% confidence intervals for age, gender, race, ISH, diabetes, and cardiovascular disease history, showing comparative risk favoring Losartan Potassium or Atenolol accordingly.*
FDA Label Image

Figure-4 (Losartan Fig4)

Figure-4 (Losartan Fig4)
A line chart showing the percentage of patients with events over 48 months, comparing Losartan Potassium (solid line) to placebo (dashed line). The chart indicates a risk reduction of 16.1% with a p-value of 0.022.*
FDA Label Image

Chemical Structure (Losartan Str)

Chemical Structure (Losartan Str)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.